-
Treating Smoldering Multiple Myeloma
A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
-
January 24: The Week in Cancer News
Studies underscore the strength of exercise recommendations, and new radiation therapy technique poised to make a flash.
by Marci A. Landsmann
-
January 17: The Week in Cancer News
Cancer incidence on the rise in younger women, and a new report issued on alcohol and health.
by Kevin McLaughlin
-
Immunotherapy Improves Survival in Bladder Cancer
New research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
-
January 10: The Week in Cancer News
Getting more calcium could lower risk for colorectal cancer, and research provides new insight into which BRCA2 mutations can lead to cancer.
by Thomas Celona
-
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live Longer
Findings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
-
January 3: The Week in Cancer News
New year brings debate about dangers of alcohol, and insurance denials continue to delay care.
by Marci A. Landsmann
Previous |
Cancer Talk
AACR Annual Meeting 2025
Immunotherapies, cancer vaccines and more from Cancer Today’s coverage of the AACR Annual Meeting 2025.
Redefining Cancer SurvivorshipAs people with advanced disease live longer, they face physical and mental health side effects. Patient advocates say research and care must focus on their unique needs.
by Thomas Celona
Family of Henrietta Lacks Works for ‘Health Intelligence’Alfred Lacks Carter Jr. and other family members honor the legacy of Henrietta Lacks by helping others better understand their health care.
by Kevin McLaughlin
Researchers Tackle Immune-related Adverse EffectsScientists present data on the risks of immune checkpoint inhibitors so more patients can tap into the treatment.
by Marci A. Landsmann